Current PSA level-Between 4 to 10 Posts on Medivizor

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 30, 2023 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Posted by Medivizor on Oct 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of whole-pelvis radiotherapy (WPRT) and prostate-only radiotherapy (PORT) in patients with node-positive prostate cancer (PC) (PC that has spread to nearby lymph nodes). The study found that WPRT improves survival without relapse in these patients, with more short-term...

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Posted by Medivizor on Oct 7, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding short-term androgen deprivation therapy (ADT) with or without pelvic lymph node radiotherapy (PLNRT) to prostate bed salvage radiotherapy (PBRT) after surgery in patients with prostate cancer (PC). The study found that adding short-term ADT and PLNRT to PBRT significantly improved...

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a new hormonal therapy, SHR3680 (rezvilutamide), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The study showed that SHR680 was well tolerated and had promising effectiveness in these patients. Some background Metastatic...

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by Medivizor on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Posted by Medivizor on Dec 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study assessed patient responses to focal thermo-ablative therapy (FTA) for oligo-recurrent prostate cancer (PCa) after pelvic radiotherapy. The data suggested that FTA therapy is a good option in these patients. Some background Oligometastatic PCa means that cancer has spread to only a few places (up to 5 metastases). It...

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Posted by Medivizor on Nov 28, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in...

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Posted by Medivizor on Aug 22, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared 2 approaches of robot-assisted radical prostatectomy (RARP) for the treatment of localized prostate cancer (PCa). The authors concluded that both transvesical (T) and posterior (P) approaches had similar results in these patients. Some background Localized prostate cancer (PCa) is cancer that is...

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Posted by Medivizor on Aug 15, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients. Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Posted by Medivizor on Jun 30, 2021 in Prostate cancer | 0 comments

In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients. Some background Surgical removal of the prostate gland is often recommended as a treatment for...

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Posted by Medivizor on May 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...

Current PSA level-Between 4 to 10 Posts on Medivizor

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of prostate-only versus pelvic radiotherapy for patients with prostate cancer spread to nearby lymph nodes.

Evaluating the effectiveness of adding short-term androgen deprivation therapy with or without pelvic lymph node treatment to prostate bed salvage radiotherapy in patients with resected prostate cancer.

Evaluating the effectiveness and safety of new antiandrogen SHR3680 in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Using focal thermo-ablative therapy for treating oligo-recurrent prostate cancer after radiotherapy.

Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.

Comparing the outcomes of transvesical or posterior robot-assisted radical prostatectomy for localized prostate cancer.

Treating castration-resistant prostate cancer that has not spread using new hormonal therapies

Does focal laser ablation improve outcomes in the long-term for patients with prostate cancer?

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Evaluation of intermittent androgen deprivation therapy for locally advanced prostate cancer.

Categories

Recent Posts

Archives

Current PSA level-Between 4 to 10 Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email